Barclays PLC Grows Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Barclays PLC lifted its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 111.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,737 shares of the company’s stock after acquiring an additional 14,647 shares during the quarter. Barclays PLC owned 0.15% of USANA Health Sciences worth $1,052,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Safe Harbor Fiduciary LLC acquired a new stake in USANA Health Sciences in the 3rd quarter worth about $30,000. KBC Group NV boosted its holdings in shares of USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares during the last quarter. BOKF NA grew its position in shares of USANA Health Sciences by 99.4% in the second quarter. BOKF NA now owns 5,526 shares of the company’s stock valued at $250,000 after purchasing an additional 2,755 shares in the last quarter. Centiva Capital LP acquired a new stake in shares of USANA Health Sciences in the third quarter valued at approximately $213,000. Finally, Quest Partners LLC purchased a new position in USANA Health Sciences during the third quarter worth approximately $250,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock opened at $33.55 on Wednesday. USANA Health Sciences, Inc. has a fifty-two week low of $31.44 and a fifty-two week high of $52.75. The firm has a market capitalization of $639.46 million, a price-to-earnings ratio of 11.86, a PEG ratio of 1.25 and a beta of 0.89. The stock has a 50 day moving average of $37.55 and a 200 day moving average of $39.06.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The firm had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. During the same period last year, the company earned $0.59 EPS. Analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on USNA. StockNews.com raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 28th. DA Davidson lifted their target price on shares of USANA Health Sciences from $35.00 to $38.00 and gave the stock a “neutral” rating in a research note on Thursday, January 2nd.

Insider Activity

In related news, Director Gilbert A. Fuller sold 675 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.33% of the company’s stock.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.